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Editor: Mohandas NarlaHepcidin is the key regulator of systemic iron homeostasis. The iron-sensingmechanisms and the role of intracel-
lular iron in modulating hepatic hepcidin secretion are unclear. Therefore, we created a novel cell line,
recombinant-TfR1 HepG2, expressing iron-response-element-independent TFRC mRNA to promote cellular
iron-overload and examined the effect of excess holotransferrin (5 g/L) on cell-surface TfR1, iron content,
hepcidin secretion andmRNAexpressions of TFRC,HAMP, SLC40A1,HFE and TFR2. Results showed that the recom-
binant cells exceeded levels of cell-surface TfR1 in wild-type cells under basal (2.8-fold; p b 0.03) and
holotransferrin-supplemented conditions for 24 h and 48 h (4.4- and 7.5-fold, respectively; p b 0.01). Also,
these cells showed higher intracellular iron content than wild-type cells under basal (3-fold; p b 0.03) and
holotransferrin-supplemented conditions (6.6-fold at 4 h; p b 0.01). However, hepcidin secretion was not higher
than wild-type cells. Moreover, holotransferrin treatment to recombinant cells did not elevate HAMP responses
compared to untreated or wild-type cells. In conclusion, increased intracellular iron content in recombinant
cells did not increase hepcidin responses compared to wild-type cells, resembling hemochromatosis. Further-
more, TFR2 expression altered within 4 h of treatment, while HFE expression altered later at 24 h and 48 h, sug-
gesting that TFR2 may function prior to HFE in HAMP regulation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Transferrin1. Introduction
Hepcidin, the 25-mer iron-hormone is secreted by the liver hepato-
cytes in response to increased systemic iron levels in the body [1,2]. It
binds to ferroportin, the iron-exporter protein on hepatocytes, duode-
nal enterocytes and splenic and liver macrophages [3–5] and causes in-
tracellular degradation of both hepcidin and ferroportin [6]. Hepcidin
thus prevents iron efﬂux via ferroportin into the circulation and acts
as the main regulator of systemic iron homeostasis. Accordingly, insuf-
ﬁcient systemic hepcidin levels lead to elevated duodenal iron absorp-
tion and uncontrolled iron efﬂux into the circulation. This causes
progressive iron accumulation in vital organs such as liver, pancreas
and heart, eventually resulting in organ failure due to iron toxicity.
These features are hallmarks of the iron-overload heredity hemochro-
matosis [7,8] and also observed in alcoholic liver disease [9,10].dical Sciences, University of
l).
. This is an open access article underThe extracellular and intracellular iron-sensing mechanisms of he-
patocytes that lead to hepcidin synthesis and secretion in response to
circulatory iron are not clearly deﬁned yet. In this context, previous
studies suggested roles of plasma transferrin (Tf) and stored intracellu-
lar iron in the induction of HAMP, gene encoding hepcidin [11–13]. In
addition, intracellular iron was proposed to induce the maturation of
pro-hepcidin into secretable bioactive hepcidin [14]. However, its pre-
cise role in hepcidin peptide secretion has not been sufﬁciently studied.
Alongside, although the proteins HFE and TFR2 on the hepatocytes are
pivotal inHAMP induction [15], their mechanisms of action,whether in-
dependent or in conjunction, remain ambiguous [16–18]. Collectively,
the complete picture of hepcidin regulation and secretion in response
to iron is yet to be fully elucidated.
Hence, here, the effect of excess holo-Tf and the consequently al-
tered intracellular iron content on hepcidin secretion (at peptide
level) and synthesis (at mRNA level) was examined simultaneously.
Since hepcidin is secreted predominantly by the hepatocytes, the
liver-derived cell line, HepG2, was chosen for the study. Cellular iron-
uptake is mediated by the cell-surface protein TfR1, which is regulated
at the iron-response element (IRE) region on its mRNA via the IRE/
iron-regulatory protein (IRP) system [19]. Here, using wild-type (Wt)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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expressed IRE-independent TFRCmRNA to diminish sensitivity towards
increasing intracellular iron content and allow intracellular iron over-
load. It was hypothesized that upon holo-Tf treatment, these recombi-
nant (rec)-TfR1 HepG2 cells would demonstrate higher intracellular
iron content and consequently, alter hepcidin peptide secretion and
HAMPmRNA responses compared to Wt cells. Previous ex vivo studies
investigated HAMP regulation only at longer time-points such as 24 h
(h), 48 h and 72 h [20–24]. Here, we studied the effects of holo-Tf on
hepcidin secretion for short-term i.e. at 30 min, 2 h and 4 h, in addition
to long-term i.e. 24 h and 48 h, in conjunction with mRNA expression
studies of key iron-related genes such as TFRC, HAMP, SCL40A1, HFE,
and TFR2.
2. Materials and methods
2.1. Cell culture
HepG2 cells (Health Protection Agency, UK) were maintained in
Eagle's Minimum Essential Medium (EMEM) (Sigma-Aldrich UK), 1%
non-essential amino acids (NEAA) (Sigma-Aldrich UK), 2 mM glutamax
(Fisher Scientiﬁc International Inc. UK), 1% antibiotic/antimycotic solu-
tion (Fisher Scientiﬁc International Inc. UK) and 10% fetal calf serum
(FCS) (Biosera, UK). Rec-TfR1 HepG2 cells expressing IRE-independent
human TFRC mRNA were created (supplementary data-1) and main-
tained in 200 μg/mLhygromycin B (Invitrogen, UK) as a selection for ex-
clusive growth of recombinant cells. TFRC-IRE mRNA response was
explored by probing the mRNA (cDNA) of rec-TfR1 HepG2 cells and
Wt HepG2 cells (as control) with the IRE-speciﬁc primers (GGTTGCTA
AGAAGCGAGCAC and TGCTCCCGATAATGTGTTAGG). As an additionalA B
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Fig. 1. Rec-TfR1HepG2 cells in basal conditions (10% FCS). (A) TFRCmRNAexpression, (B) Intr
genes in rec-TfR1 HepG2 cells in comparison with Wt HepG2 cells and (E) relative mitochondr
compared to Wt HepG2 cells.reference, the cDNA was probed with TFRC-speciﬁc primers (Supple-
mentary Fig. 1A–1B). Results showed diminished TFRC-IRE-speciﬁc am-
pliﬁcation in the rec-TfR1 HepG2 cells (supplementary Fig. 1A),
indicating diminished IRE-related responsiveness, as desired for the
study. Also, a HepG2 cell line with the unmodiﬁed plasmid vector
[HepG2 (p) cells] was created for pre-iron-supplementation studies
[(supplementary data-2 and supplementary ﬁgures (2A-2C)].
2.2. Holo-Tf supplementation
The iron saturation of holo-Tf and the iron content of the treatment
medium were assessed (supplementary data-3 and supplementary
Fig. 3A–3B). Cells were seeded at a density of 5 × 105 per well in a 6-
well plate in maintenance medium (with and without hygromycin B
for rec-TfR1 HepG2 cells and Wt cells, respectively) for 72 h. For the
next 24 h, all cells were incubated in fresh hygromycin-free mainte-
nancemedium. Then, the cells were treatedwith 5 g/L holo-Tf prepared
in serum-free EMEM (0 g/L) for the desired period and assessed for var-
ious parameters.
2.3. Determination of intracellular iron content and assessment of mito-
chondrial activity
Cellular iron content determined by the ferrozine assay [25] was
expressed asnmoles of iron permgof protein, as quantiﬁed by the Brad-
ford method. Mitochondrial activity was assessed by using the MTT
assay [26]. To compare the mitochondrial activity of cells in between
different treatments, 2.5 × 104 cells were seeded per well of a 96 well
plate in maintenance medium. The plate was incubated overnight at
37 °C in a humidiﬁed atmosphere with 5% CO2. The following day, theC
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with warm PBS to remove traces of the maintenance medium. Treat-
mentmedia were then added to eachwell and the plateswere again in-
cubated at 37 °C in a humidiﬁed atmosphere with 5% CO2. On
completion of the treatment exposure period, the old media were re-
placed with 200 μL of fresh media per well. This was followed by addi-
tion of 5 μL per well of 5 mg/mL of MTT prepared in PBS. The plates
were incubated at 37 °C for 2 h, the media were removed and 100 μL
DMSO was added to each well. Plates were incubated at RT for 15 min,
vortexed for 30 s and absorbance was read at 550 nm using a spectro-
photometer. The absorbance values of blanks (medium only) were
subtracted from controls and treated samples. This assay was appropri-
ate for our study because it measures the mitochondrial activity [26]
and themitochondrion is a major organelle for ROS production [27], es-
pecially under excess iron conditions [28,29]. Thus,mitochondrial activ-
ity was chosen as a marker of cell/mitochondrial health over other
markers.2.4. Cell-surface TfR1 expression
Cells were harvested using TrypLE Express (ThermoFisher Scientiﬁc,
UK), followed by centrifugation for 4 min at 89 ×g. Cells were
suspended in PBC (PBS containing 0.15% BSA and 1 mM calcium chlo-
ride) and transferred to a 96-well plate (2 × 105 cells per well) and cen-
trifuged at 1260 ×g for 30 s. To each well, 20 μL of 16 mg/mL blocking
IgG was added. Human TfR1 antibody (Abcam, UK) [5 μg/mL in PBC)]
was added to each test well and PBC was added to the control wells.
Cells were incubated for 45 min on ice. Following washing, the cells
were incubated with 10 μg/mL of FITC-labeled secondary antibody
STAR9B rabbit F (ab′) 2 anti-mouse IgG (ABD Serotec, UK). After incuba-
tion for 30min on ice, cellswerewashedwith PBC again. Cell layer at the
bottom of each well was suspended in 400 μL of PBS and TfR1 expres-
sion was analyzed by ﬂow cytometry [30]. For the gating of cells for
ﬂow cytometry, ﬁrst, live cells were selected based on the forward and
side scatter. On the selected cell population, the positive threshold
was determined based on the staining results obtained in the absence
of the TfR1 antibody (cells treated with secondary antibody only). This
selected a cell population of TfR1positive cells. Then, the position of
the gate was kept ﬁxed while assessing samples fromWt and rec-TfR1
HepG2 cells and samples from different treatment conditions for both
the cell lines. This enabled relative comparisons between the cell
types and in between treatments.##
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Fig. 2. Effect of holo-Tf treatment on TfR1 cell-surface expression. HepG2 cells were2.5. Gene expression analysis
Primers (Invitrogen, UK) for expression analyses of the genes TFRC
(NCBI accession no.NM_001128148.1), HAMP (NCBI accession
no.AF309489.1) and GAPDH (NCBI accession no. NM_002046.4) were
designed [Primer 3 (http://frodo.wi.mit.edu/)] (supplementary data-4).
RNAwas extracted using TRI reagent (Sigma-Aldrich, UK) and convert-
ed to cDNA using QuantiTect reverse transcription kit (Qiagen, UK), as
per manufacturer's protocol. Gene expression was analyzed through
real-time PCR by using Quantifast SYBR green kit (Qiagen, UK) accord-
ing to the manufacturer's protocol. Real-time PCRs were carried out in
the Rotor-gene Q machine (Qiagen, UK) and the results were analyzed
through Rotor-gene software series 1.7. Data was analyzed by the
relative quantiﬁcation method, Delta-Delta Ct (ΔΔCt) and expressed as
2 -ΔΔCt [31].treated with 5 g/L holo-Tf up to 48 h and total cell-surface expression of TfR1 before
treatment (basal conditions) and after treatment was studied by ﬂow cytometry.
Representative images for each treatment for Wt HepG2 cells and rec-TfR1 HepG2 cells
have been shown in supplementary Fig. 4 and the effect of treatment has been
summarized in the above ﬁgure. Data is presented as mean ± SEM (n= 3–6). *p b 0.03
and**p b 0.01 compared to Wt HepG2 cells at the corresponding time-point; #p b 0.04
compared to Wt HepG2 cells in basal conditions; ##p b 0.01 compared to Wt HepG2
cells following treatment at 24 h.2.6. Hepcidin peptide levels
The concentration of hepcidin peptide secreted in the cellmediawas
measured by using a previously well-described immunoassay by
Busbridge et al. [32].2.7. Statistical analysis
Data analysis was performed using one-way or two-way ANOVA,
with post-hoc analysis by Tukey's test using the software SPSS, version
22. The level of signiﬁcance was set at p b 0.05. Data was presented as
mean ± SEM.
3. Results
3.1. Characterization of novel rec-TfR1-HepG2 cells in basal conditions
The rec-TfR1 HepG2 cells showed signiﬁcantly higher TFRC mRNA
expression (2.2-fold; p b 0.03) and iron content than Wt cells (3-fold;
p b 0.03) (Fig. 1A and 1B). However, hepcidin secretion levels were sim-
ilar to the Wt cells (Fig. 1C). These cells expressed substantially higher
levels of SLC40A1 (8.8-fold; p b 0.05), but did not signiﬁcantly differ
from the Wt HepG2 cells in mRNA expressions of HAMP, HFE and TFR2
(Fig. 1D), whilst mitochondrial activity increased by 30% (p b 0.05)
(Fig. 1E). Under basal conditions, the rec-TfR1 HepG2 cells displayed
signiﬁcantly higher cell-surface TfR1 levels than Wt cells (2.8-fold;
p b 0.03) (Fig. 2).
3.2. Rec-TfR1-HepG2 cells under holo-Tf-supplemented conditions
3.2.1. Cell-surface TfR1 and TFRC mRNA expression
Following holo-Tf treatment, theWt cells displayed a signiﬁcant de-
crease in cell-surface TfR1 over time at 24h (p b 0.04),which further de-
clined at 48 h (p b 0.01) (Fig. 2 and supplementary Fig. 4). Conversely,
the rec-TfR1 HepG2 cells maintained high levels following 24 h and
48 h of holo-Tf treatment and showed signiﬁcantly higher levels than
Wt cells at these times (p b 0.01) (Fig. 2 and supplementary Fig. 4A).
The rec-TfR1 HepG2 cells showed no statistically signiﬁcant difference
in TfR1 levels under holo-Tf-treated and basal conditions (Fig. 2). In ad-
dition, TFRCmRNA expressionwas assessed and compared to respective
untreated (0 g/L) cells at each corresponding time-point. The Wt cells
showed signiﬁcantly decreased TFRC mRNA expression at 2 h
(p b 0.05), 4 h (p b 0.05) and 24 h (p b 0.05) (Fig. 3). In contrast, rec-
TfR1HepG2 cells showed signiﬁcant 3-fold elevations in TFRCmRNA ex-
pression at 2 h (p b 0.05) and 24 h (p b 0.02) (Fig. 3). In the Wt HepG2
cells, decreased TFRCmRNA expression following holo-Tf treatment for
24 h and 48 h (Fig. 3) correlated with decreased cell-surface TfR1 levels
observed at these time-points (Fig. 2). However, in rec-TfR1 HepG2
cells, the correlation was less clear.
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Upon holo-Tf treatment, the rec-TfR1 HepG2 cells showed higher in-
tracellular iron content than Wt cells at 30 min (3.3-fold, p b 0.03), 2 h
(3.7-fold, p b 0.01), 4 h (6.6-fold, p b 0.01), 24 h (5.7-fold, p b 0.01)
and 48 h (2.2-fold, p b 0.01) (Fig. 4). Even under holo-Tf deprivation
(0 g/L), the rec-TfR1 HepG2 cells showed higher intracellular iron con-
tent than Wt cells at 30 min (3.6-fold, p b 0.01), 2 h (3.2-fold,
p b 0.01), 4 h (2.8-fold, p b 0.01), 24 h (2.5-fold, p b 0.01) and 48 h
(1.9-fold, p b 0.03) (Fig. 4).
Over time, the Wt cells showed no major variation in intracellular
iron content upon holo-Tf deprivation and treatment (Fig. 4). In con-
trast, during short-term treatment, the rec-TfR1 HepG2 cells showed a
pattern of increasing iron-uptake compared to respective untreated
(0 g/L) cells at the same time-point i.e. no signiﬁcant uptake at
30 min, a 1.4-fold increase at 2 h (p b 0.02) and a 3.1-fold increase at
4 h (p b 0.01) (Fig. 4). Also, a 2.4-fold increase (p b 0.01) in iron-
uptake was observed at 24 h of holo-Tf treatment (Fig. 4).3.2.3. Hepcidin peptide levels
Despite the substantially higher intracellular iron content in rec-
TfR1 HepG2 cells (Fig. 4), hepcidin secretion in these cells was not
higher than Wt cells (Fig. 5A and 5B). However, both, Wt and rec-TfR1
HepG2 cells secreted signiﬁcantly higher levels of hepcidin upon holo-
Tf supplementation in comparison to their respective untreated
(0 g/L) cells (Fig. 5). For example, the Wt HepG2 cells showed signiﬁ-
cantly elevated hepcidin secretion at 2 h (p b 0.02), 4 h (p b 0.02),
24 h (p b 0.02) and 48 h (p b 0.02) (Fig. 5A). Likewise, the rec-TfR1
HepG2 cells showed elevated hepcidin secretion at 30 min (p b 0.05),
2 h (p b 0.02), 4 h (p b 0.02), 24 h (p b 0.02) and 48 h (p b 0.02) (Fig. 5B).**
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ally decreased over time in both, Wt and rec-TfR1 HepG2 cells (Fig. 5);
from 2 h to 24 h (1.6-fold; p b 0.05), and further decreased at 48 h
(2.2-fold; p b 0.02) in Wt cells (Fig. 5A) and from 30 min to 24 h (3.1-
fold; p b 0.04), and further decreased at 48 h (3.4-fold; p b 0.03) in re-
combinant cells (Fig. 5B).
3.2.4. Gene expression analyses
The mRNA expression of core iron-related genes were assessed and
compared to respective untreated (0 g/L) cells at each corresponding
time-point. In Wt cells, HAMPmRNA expression signiﬁcantly increased
at 4 h (2.2 fold; p b 0.05) and 24 h (1.6 fold; p b 0.02), whereas in rec-
TfR1 HepG2 cells, it signiﬁcantly increased only at 2 h (1.5-fold;
p b 0.02) (Fig. 6A). While SLC40A1 mRNA expression remained unal-
tered in Wt cells (Fig. 6B), in rec-TfR1 HepG2 cells, an unaltered re-
sponse at 30 min, a 1.8-fold increase at 2 h (p b 0.05) and a 3-fold
increase at 4 h (p b 0.05) was observed, followed by unchanged expres-
sion at 24 h and 48 h of holo-Tf treatment (Fig. 6B).
Both, Wt and rec-TfR1 HepG2 cells showed no change in HFEmRNA
expression during short-term treatment (Fig. 7A). However, it was
down-regulated at 48 h (2.7-fold, p b 0.05) in Wt cells and at 24 h
(2.7-fold, p b 0.05) in rec-TfR1 HepG2 cells (Fig. 7A). In contrast, TFR2
mRNA expression remained unaltered at 24 h and 48 h and altered ear-
lier during short-term treatment in both, Wt and rec-TfR1 HepG2 cells
(Fig. 7B). However, the two cell types exhibited different TFR2mRNA re-
sponses to treatment. In Wt cells, TFR2 mRNA expression was up-
regulated at 30 min (2.3-fold, p b 0.05), and later again at 4 h (2.9-
fold, p b 0.05), whereas in rec-TfR1 HepG2 cells, TFR2mRNA expression
was signiﬁcantly reduced at 4 h (p b 0.01), compared to untreated
(0 g/L) cells (Fig. 7B). Following 5 g/L treatment, there was no major****
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at 48 h (p b 0.05), compared to untreated (0 g/L) cells at the same
time-point (Fig. 8).
4. Discussion
The liver-secreted iron-hormone hepcidin is the master regulator of
systemic iron homeostasis in the body. However, the iron-sensing
mechanisms in the hepatocytes are not fully understood. A role of intra-
cellular iron inmodulating hepcidin secretion [14] andHAMPmRNA ex-
pression [11–13] was suggested, but not fully elucidated. Accordingly,
here, for the ﬁrst time, novel rec-TfR1 HepG2 cells were created that
expressed IRE-independent TFRCmRNA to diminish sensitivity towards
high intracellular iron and to allow continuous iron-uptake upon holo-
Tf supplementation. In these cells, the combined effect of excess extra-
cellular holo-Tf and the subsequently increased intracellular iron on
hepcidin secretion was examined over time for the ﬁrst time, in con-
junction with mRNA expression studies of key iron-related genes like
TFRC, HAMP, SLC40A1, HFE and TFR2. The responses of this novel cell
line were compared with those of the Wt cells.
4.1. Deregulated cell-surface TfR1 and high iron content in recombinant
cells
Upon holo-Tf treatment, the Wt cells down-regulated cell-surface
TfR1 levels over time (Fig. 2). This was an anticipated response because
the IRE-replete TFRC transcripts would sense increments in intracellular
iron content via the IRE/IRP system and eventually decrease TfR1protein expression on cell-surface to prevent further iron-uptake [33].
Accordingly, and as expected, the Wt cells showed no major variation
in intracellular iron content following holo-Tf treatment (Fig. 4), resem-
bling physiological conditions and other studieswhere 4.5 g/L of holo-Tf
treatment for 48 h did not signiﬁcantly increase iron content [34].
In contrast, the rec-TfR1 HepG2 cells displayed several fold higher
cell-surface TfR1 than Wt cells under basal and prolonged holo-Tf-
supplemented conditions (Fig. 2), despite their several fold higher intra-
cellular iron content thanWt cells (Figs. 1B and 4). Such an unexpected
response could be because the recombinant TFRC construct in rec-TfR1
HepG2 cells was devoid of the IRE region and therefore independent
from the IRE-mediated iron-regulatory mechanisms [35]. This iron-
insensitive feature was also reﬂected through up-regulated TFRC
mRNA expression following holo-Tf treatment, unlike the Wt cells that
showed down-regulated expression (Fig. 3). In Wt cells, the reduced
TFRCmRNA expression at 24 h (Fig. 3) is consistent with the previously
observed decrease following 2.5 g/L of holo-Tf treatment for 24 h [24].
Thus, contrasting theWt cells, rec-TfR1 HepG2 cells demonstrated con-
stitutively elevated cell-surface TfR1regardless of excess extracellular
holo-Tf and high intracellular iron content, as required for this study.
Both,Wt and rec-TfR1 HepG2 cells exceeded basal levels of hepcidin
secretion upon holo-Tf treatment and decreased hepcidin levels over
time upon holo-Tf deprivation (0 g/L) (Figs. 5 and 1C). This is similar
to the human response where increased circulatory iron levels lead to
increased circulatory hepcidin levels [1,36–38] and reduced hepcidin
response prevails under iron deﬁciency [37,39]. Interestingly, upon
holo-Tf treatment, the Wt cells exceeded the basal level by 1.7-fold at
4 h and markedly reduced hepcidin secretion at 24 h (Figs. 1C and 5).
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Fig. 6. Effect of holo-Tf treatment on HAMP and SLC40A1mRNA expression. Upon 5 g/L holo-Tf treatment, mRNA expression of (A) HAMP and (B) SLC40A1 in the HepG2 cells was
assessed and expressed relative to respective untreated (0 g/L) cells at the corresponding time-point. Data is presented as mean ± SEM (n = 3). *p b 0.05, **p b 0.02 compared to
untreated (0 g/L) cells at the corresponding time-point.
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65 mg of iron led to a 2-fold increase in hepcidin levels after 4 h and
returned to baseline levels after 24 h [38].
The intracellular iron status of the cells is not only related to iron-
uptake via TfR1 but also related to cellular iron efﬂux mediated by reg-
ulations in the iron-efﬂux gene SLC40A1. Here, SLC40A1 expression
remained unaltered in Wt HepG2 cells at all time points (Fig. 6B). In
the rec-TfR1 HepG2 cells, it was upregulated at the early contiguous
time points (2 h and 4 h), but remained unaltered at the longer contig-
uous time points (24 h and 48 h). This difference in the responses be-
tween short-term and long-term treatments could be due to the
presence of 5′ IREs on the SLC40A1 mRNA. These sense intracellular
iron-increments in the rec-TfR1 HepG2 cells at a particular treatment
time-point and resultantly increase expression to promote cellular
iron-efﬂux [19]. Thus, its expression would be determined by the intra-
cellular iron status at a particular treatment time-point and therefore
vary.
4.2. Hepcidin levels and intracellular iron content
The rec-TfR1 HepG2 cells demonstrated higher iron content thanWt
cells under basal and holo-Tf-supplemented conditions (Figs. 1B and 4).
However, hepcidin secretion in the rec-TfR1 HepG2 cells did not exceed
the levels secreted by the Wt cells, in neither basal nor holo-Tf-
supplemented conditions (Figs. 1C and 5).
Thus, here, hepcidin secretion did not alter in proportion to the in-
creased intracellular iron levels in the rec-TfR1 HepG2 cells, compared
to Wt cells. This suggests that possibly, the proposed post-translation
maturation of pro-hepcidin to bioactive hepcidin [14] may well be me-
diated by intracellular iron levels, requiring only subtle amounts of iron-uptake to trigger thematuration of pro-hepcidin to secretable hepcidin.
This was reﬂected in Wt cells, which, following holo-Tf treatment,
exceeded basal hepcidin secretion levels (Figs. 1C and 5) without any
major iron-uptake (Fig. 4).
4.3. HAMP mRNA response to holo-Tf treatment in recombinant cells
Following holo-Tf supplementation, although intracellular iron
levels in rec-TfR1 HepG2 cells were substantially higher than Wt cells
(Fig. 4), HAMPmRNA responses did not proportionately exceed the re-
sponses ofWt cells (Fig. 6A). In fact, the rec-TfR1HepG2 cells showed an
elevated response only at 2 h while the Wt cells showed elevated ex-
pression at 4 h and 24 h (Fig. 7A). This could be due to several reasons.
Firstly, excess cell-surface TfR1on rec-TfR1 HepG2 cells would have
changed the native ratios of TfR1 with its hepcidin-inducing binding
partners on the cell-surface, HFE and TFR2 [40,41]. This may have
caused the majority of the HFE to bind to TfR1, aiming to regulate
iron-uptake [40,42], thereby limiting the availability of free HFE for
HAMP induction [43], with or without TFR2 [16,17]. Secondly, the
down-regulated expression of TFR2 following holo-Tf treatment
(Fig. 7B) may have prevented HAMP up-regulation in rec-TfR1 HepG2
cells (Fig. 6A). In contrast, the Wt cells showed signiﬁcantly elevated
TFR2mRNA responses at 30min and 4 h (Fig. 7B) that matched the pat-
tern of HAMP mRNA expression in these cells (Fig. 6A). This
reemphasizes and supports the role of TFR2 inmodulatingHAMP induc-
tion following holo-Tf stimulus [20,44].
Unlike Tf, which is known to inﬂuence hepcidin expression [45], the
relationship between TfR1 (membrane-bound or soluble) and hepcidin
expression remains unclear. In this study, the presence of high levels of
membrane-bound TfR1 on rec-TfR1 HepG2 cells did not correlate with
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Fig. 7. Effect of holo-Tf treatment on HFE and TFR2mRNA expression. Upon 5 g/L holo-Tf treatment, mRNA expression of (A) HFE and (B) TFR2 in the HepG2 cells was assessed and
expressed relative to respective untreated (0 g/L) cells at the corresponding time-point. Data is presented as mean ± SEM (n= 3). *p b 0.05 compared to untreated (0 g/L) cells at the
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Tf concentration (5 g/L) utilized provided the conditions for holo-Tf –
TfR1 binding to occur, as demonstrated by the excess cellular iron-
uptake by the rec-TfR1 HepG2 cells (Fig. 4). Following holo-Tf treat-
ment, these cells demonstrated up to 6.6-fold higher intracellular iron
content than the Wt HepG2 cells and showed increased iron-uptake
over a 4 h period (Fig. 4). This suggests that any soluble TfR1 in the me-
diumhadnot signiﬁcantly affected the binding of holo-Tfwith TfR1, else
we would not expect to see increased iron uptake as observed in this
study over the 4 h time period (Fig. 4). The binding of holo-Tf with
TfR1 would also lead to potential HAMP induction via the holo-Tf-TfR1
pathway. This reduced the probability that the diminished HAMP0
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Fig. 8. Effect of holo-Tf treatment on mitochondrial activity. Following 5 g/L holo-Tf treatm
untreated (0 g/L) cells at the corresponding time-point. Data is presented as mean ± SEM (n=induction could be due to limited availability of holo-Tf, resulting from
the probable binding of soluble TfR1 to holo-Tf in themedium. Further-
more, increased circulating soluble TfR1 generally occurs in Iron Deﬁ-
ciency Anemia reviewed in [46,47].
The BMP/SMAD,MAPK, IL6-JAK/STAT3,Matripase-2/HJV and hypox-
ia pathways are important in regulating HAMPmRNA expression [7,8]
and investigation into these pathwayswould certainly lead to improved
insights into hepcidin signaling. However, these pathways would high-
light the transcriptional regulation of hepcidin and not hepcidin peptide
secretion. The latter was the focus of this study, whichwas based on the
previously proposed role of intracellular iron in the maturation of pro-
hepcidin to release the bioactive 25-mer hepcidin [14]. Accordingly, it*
/L 5 g/L 0 g/L 5 g/L 0 g/L 5 g/L
4 h 24h 48h
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ent, mitochondrial activity of HepG2 cells was assessed and expressed in comparison to
3–6). *p b 0.05 compared to Wt HepG2 cells.
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morematuration of pro-hepcidin to secretemore hepcidin. Thus, the ef-
fect of excess intracellular iron (as in these iron-overloaded recombi-
nant cells) on hepcidin peptide secretion was evaluated, which has
not been sufﬁciently studied so far, rather thanHAMPmRNA regulation,
which has been extensively studied. Moreover, each of these signal
transduction pathways is dynamic, involves several proteins and there-
fore each pathway accounts for an independent study on its own. This
was beyond the scope of the present study, which prioritized hepcidin
peptide secretion over regulation of HAMP transcription.
4.4. TFR2 and HFE mRNA expression in recombinant cells
In both,Wt and rec-TfR1 HepG2 cells, HFEmRNA responses to holo-
Tf treatment remained unchanged during short-term treatment and al-
tered later at 24 h and 48 h (Fig. 7A). The down-regulation inHFEmRNA
expression at 24 h in the Wt cells is similar to that observed previously
upon 4.5 g/L holo-Tf treatment [34]. Unlike the HFE mRNA responses,
TFR2mRNA responses signiﬁcantly altered during short-term treatment
and remained unaltered at 24 h and 48 h in both the cell lines (Fig. 7B).
In the Wt cells, this was also observed in earlier studies where TFR2
mRNA expression remained unchanged after 24 h of 4 g/L holo-Tf treat-
ment [20]. Together, the data suggests that TFR2may act prior to HFE in
iron and hepcidin regulation, as also proposed earlier [20,38].
4.5. Virtual hemochromatosis
The rec-TfR1 HepG2 cells displayed several “hemochromatotic”
characteristics such as hepcidin secretion disproportionate to iron-
overload (Figs. 5 and 4), insufﬁcient HAMP mRNA response upon
holo-Tf stimulus (Fig. 6A) [48], up-regulated SLC40A1mRNA expression
(Fig. 6B) [38,49] and putative digression from the normal physiological
ratio between TfR1 andHFE on the cell-surface (Fig. 2). Thus, these cells
may be described as “virtually hemochromatotic” as the cells displayed
several “hemochromatotic” characteristics despite possessing theWt al-
leles of the hepcidin-inducing genes [16,17,20], mutations in which
cause hemochromatosis [7].
5. Conclusion
The novel rec-TfR1 HepG2 cells showed constitutively over-
expressed cell-surface TfR1 and higher intracellular iron content than
Wt cells under basal and holo-Tf supplemented conditions. However,
under the conditions studied here this did not lead to higher hepcidin
secretion levels compared to Wt cells, suggesting other regulatory
mechanisms are involved.
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